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Background: This study aims at evaluating the cost-effectiveness of a 2-dose schedule human papillomavirus (HPV)
vaccination programme of HPV and human immunodeficiency virus (HIV) naïve 12-year-old girls, in addition to
cervical cancer (CC) screening alone, in South Africa. The study aims to account for both the impact of the vaccine
among girls who are HIV-positive (HIV+) as well as HIV-negative (HIV-) population.
Methods: A previously published Markov cohort model was adapted to assess the impact and cost-effectiveness of
a HPV vaccination programme in girls aged 12 years (N = 527 900) using the AS04-adjuvanted HPV-16/18 vaccine
from a public payer perspective. Two subpopulations were considered: HIV- and HIV+ women. Each population
followed the HPV natural history with different transition probabilities. Model input data were obtained from the
literature, local databases and Delphi panel. Costs and outcomes were discounted at 5 %. Extensive sensitivity
analyses were conducted to assess the robustness of the evaluation.
Results: Implementation of the AS04-adjuvanted HPV-16/18 vaccine in combination with current cytological
screening in South African girls could prevent up to 8 869 CC cases and 5 436 CC deaths over the lifetime of a
single cohort. Without discounting, this HPV vaccine is dominant over screening alone; with discounting, the
incremental cost-effectiveness ratio is ZAR 81 978 (South African Rand) per quality-adjusted life years (QALY) gained.
HPV vaccination can be considered cost-effective based on World Health Organization (WHO) recommended threshold
(3 x gross domestic product/capita = ZAR 200 293). In a scenario with a hypothetical targeted vaccination in a HIV+
subpopulation alone, the modelled outcomes suggest that HPV vaccination is still cost-effective, although the
incremental cost-effectiveness ratio increases to ZAR 102 479. Results were sensitive to discount rate, vaccine
efficacy, HIV incidence and mortality rates, and HPV-related disease transition probabilities.
Conclusions: The AS04-adjuvanted HPV-16/18 vaccine can be considered cost-effective in a South African
context although the cost-effectiveness is expected to be lower in the HIV+ subpopulation than in the overall
female population. With improved access to HIV treatment, the HIV mortality and incidence rates are likely to
be reduced, which could improve cost-effectiveness of the vaccination programme in South Africa.
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Human papillomavirus (HPV) is the necessary cause of
cervical cancer (CC) [1], with an estimated 528 000 annual
incident CC cases and 266 000 CC deaths worldwide in
2012 [2]. High-risk regions, with age-standardised inci-
dence over 30/100 000 women, include Eastern Africa
(42.7/100 000), Melanesia (33.3/100 000), Southern Africa
(31.5/100 000) and Middle Africa (30.6/100 000) [2]. Most
frequent HPV types found in CC are types HPV-16 and
HPV-18 which account for approximatively 70 % of all
cases worldwide [3, 4]. Many of the regions with high CC
incidence, such as South Africa, are also burdened with
high incidence of human immunodeficiency virus (HIV)
infection [5, 6]. The high CC incidence could be partially
related to the high HIV incidence. Individuals infected
with HIV have an increased risk of HPV infection and the
associated subsequent disease as a result of impaired im-
munity [7, 8]. A strong association between HIV-positive
(HIV+) status and the prevalence of oncogenic HPV types,
specifically HPV-16 and HPV-18, has been previously
documented [7, 9, 10].
Three HPV vaccines are available throughout the world:
the AS04-adjuvanted HPV-16/18 vaccine (Cervarix®,
GSK), the HPV-6/11/16/18 vaccine (Gardasil, Merck &
Co., Inc.) and the HPV-6/11/16/18/31/33/45/52/58 vaccine
(Gardasil 9, Merck & Co., Inc.). These vaccines can be
used for the prevention of HPV-related diseases such as CC.
Efficacy of these vaccines has been demonstrated in adoles-
cents and adult women [11–15]. Moreover, HPV vaccines
clinical trials in HIV-infected individuals have shown that
these vaccines have clinically acceptable safety profiles and
are immunogenic [16, 17].
Up to mid-2014, more than 50 countries worldwide
introduced vaccination against HPV in their national im-
munisation programme for girls [18] including South
Africa [19]. It has been reported that more countries are
preparing to offer pre-adolescent girls HPV vaccination,
including many African countries where a high HIV
prevalence exists [20].
A systematic review on the cost-effectiveness, clinical
impact and health economic impact of HPV vaccin-
ation concluded that routine vaccination of girls is
cost-effective compared with CC screening alone [21].
One South African study reported an incremental cost-
effectiveness ratio (ICER) per quality-adjusted life-year
(QALY) gained of 1 078 US dollar (USD) from a health
service perspective [22]. However, to our knowledge,
no model explicitly has taken into account the specifi-
city of a HIV infected subpopulation in South Africa.
Given the specific epidemiology of HPV infection and
associated disease among this specific population, ac-
counting for these in health economic evaluations in
countries with a high prevalence of HIV may influence
the cost-effectiveness of the implementation of a HPVvaccination programme. Also of interest would be to
assess the effect of current change in HIV treatment
and epidemiology on the cost-effectiveness of the HPV
vaccination.
This study aims to assess the cost-effectiveness from a
public payer perspective of a 2-dose AS04-adjuvanted
HPV-16/18 vaccination programme added to the current
CC screening programme, compared with the current
CC screening programme (Papanicolaou smear test; Pap)
alone in South Africa accounting for both the impact of




A previously published lifetime Markov process cohort
decision tree with a one year cycle length focusing on
oncogenic HPV was adapted to account for both HIV+
and HIV- subpopulations [23]. The model consisted of a
series of health states representing the natural history of
HPV infection and CC (see Fig. 1 for details) as in the
initial model. The initial model was however duplicated
to reproduce HPV natural history in both the HIV+ and
HIV- subpopulations. Subjects moved between different
health states over annual cycles throughout the disease
process, governed by transition probabilities specific for
each health state. Throughout the model, a proportion
of the population yearly acquired HIV at an age-specific
incidence rate reported for South Africa hence moving
to the HIV+ sub-model.
Population
A 12-year-old girls’ cohort entered the model and was
followed over lifetime. It was assumed that this cohort
was both HIV- and HPV-naïve at the start of the simu-
lation (i.e. mother-to-child HIV transmission was not
included in the model). Based on 2011 mid-year popu-
lation estimates in South Africa, a cohort of 527 900
girls aged 12 years was considered for this analysis [24].
Model input data and assumptions
Natural history related to oncogenic HPV
Different transition probabilities were applied to the
HIV-positive and negative populations to account for
the specificities of the acquisition and natural history of
HPV infection in these two subpopulations, as docu-
mented by a recent systematic literature review [25].
Age-dependent HIV incidence was taken into account to
estimate the proportion of the population moving from
the HIV- to HIV+ over the lifetime of the cohort. The
transition probabilities related to the natural history of
oncogenic HPV among HIV- subpopulation remained
unchanged compared with Suarez et al. [23]. Those re-
lated to HIV+ subpopulation were consolidated from the
Fig. 1 Model structure. The model assesses the impact and cost-effectiveness of a HPV vaccination on HIV- and HIV+ subpopulations, considering
the HPV natural history with different transition probabilities. The left panel shows the natural history of HPV infection, with overlay of CC screening
and vaccination. At any time during the cohort’s life, subjects can move from the left panel (HPV natural history, HIV-) to the right panel (HPV
natural history, HIV+). CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; CIN1-Onc, oncogenic HPV types
caused CIN1; det, subjects with disease detected through screening (same pathways but different probabilities), HIV, human immunodeficiency
virus; HIV-, HIV-negative; HIV+, HIV-positive; HPV, human papillomavirus; Pap, Papanicolaou smear test; HPV-Onc, oncogenic HPV types
Li et al. BMC Infectious Diseases  (2015) 15:566 Page 3 of 18findings of a targeted literature review via PubMed using
search terms related to HPV, HIV, cervix and neoplasm. Ar-
ticles published before February 2014 were retrieved and the
abstracts and selected manuscripts were assessed by a single
reviewer. When data for HIV+ subjects were unavailable in
the literature, conservative assumptions were made (i.e. same
cervical intraepithelial neoplasia [CIN] treatment success
rate in HIV+ and HIV- subpopulation). See Additional file 1.
The model was calibrated on incidence and mortality
of CC in the HIV- population in South Africa by adjust-
ing the transition probability from persistent CIN2/3 to
CC as this parameter could not be retrieved from the lit-
erature due to the lack of these data for ethical reasons.
For the HIV+ population, we assumed a multiplication
factor of 2 for this specific transition probability, based
on a prospective cohort study conducted by Massad
et al. on progression and regression rates for abnormal
cervical cytology among HIV-infected women [26]. The
study reported greater progression rate within 6 months
after diagnosis among HIV+ when compared with HIV-
women (14 % vs. 7 %). See Table 1 for details on all an-
nual transition probabilities included in the model.
Country specific data
Parameters related to HPV and HIV disease-specific inci-
dence, background mortality rate, disease management,including CC screening and treatment of precancerous
lesions and cancer were adapted to the South African
setting and retrieved from the literature, local databases or
expert opinion (see Table 2).
Cervical cancer screening
South Africa CC screening guidelines recommend that
each woman from the age of 30 should be screened every
10 years at no cost [27]. The start age for CC screening
was set to 30 years of age and at a frequency of once every
3 years until 60 years of age, as the South Africa national
guideline and World Health Organization (WHO) recom-
mend this frequency as best case for CC prevention or
when resources allow for it [27, 28]. A cytological screen-
ing (i.e., Papanicolaou smear test) was assumed and sensi-
tivity for the detection of cervical abnormalities with this
test was retrieved from a meta-analysis on this subject.
See Table 2 for details.
Utilities
Utilities for precancerous lesions, CC and CC survivors
in South Africa were not available from the literature.
Disutility values used were therefore retrieved from pub-
lished reports for other settings and assumed to be iden-
tical for HIV- and HIV+ subpopulations (see Table 3)
[29–33]. Baseline utility values in the absence of HPV









HPV-Onc to CIN1 0.049 Adjusted from [60] (0.15 after
36 months and 0.21 after 60 months)
0.096 [49]
HPV-Onc to CIN2/3 0 Spontaneous progression from
HPV-onc to CIN2/3 within 1 year;
assumed to be 0
0 Assumption
(same as HIV- subpopulation)
HPV-Onc clearance to normal 0.293–0.553 [29, 60–62] 0.212 [49]
CIN1 to CIN2/3 0.091 [61–63] 0.098 [49]
CIN2/3 cured 0.227 [61–63] 0.227 Assumption
(same as HIV- subpopulation)
CIN2/3 to CIN1 0 Spontaneous regression from CIN2/3
to CIN1 within 1 year; assumed to be 0;
all patients cured going to no HPV
assumption
0 Assumption
(same as HIV- subpopulation)
HIV- CIN2/3 to persistent
CIN2/3
0.114 [62, 63] 0.114 Assumption
(same as HIV- subpopulation)
Persistent CIN2/3 to cervical
cancer
Age 15: 0.00 % Based on estimated CIN2/3 and reported
cervical cancer progression rates
Age 15: 0.00 % Applied relative risk ratio of 2 for
HIV+ based on the progression rate
from LSIL to HSIL [64]Age 35: 1.10 % Age 35: 2.20 %
Age 45: 2.52 % Age 45: 5.04 %
Age 60: 7.56 %a Age 60: 15.12 %a
aThe model calibration led to 0.12 % yearly increase from 20 years of age to 35 years, 0.2 % yearly increase from 36 years of age to 45 years, 0.3 % yearly increase
from 45 years of age to 55 years, and 0.4 % yearly increase from 60 years of age onwards
CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; HPV, human papillomavirus; HPV-Onc, oncogenic HPV types; HIV, human
immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV + positive; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions
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sumed to be 1 and 0.81, respectively [34].
Resource utilisation and disease-related costs
Only direct medical costs were considered in this ana-
lysis. In accordance with the South Africa Pharmacoeco-
nomic Guidelines, direct non-healthcare-related-costs
and indirect costs associated with quality-of-life and
productivity loss were not included [35].
A two-round Delphi panel with 8 South African experts
in the field of gynaecologic oncology was conducted to
collect medical management-related resource use for pa-
tients with HPV-related disease in South Africa. The over-
all resources used for the treatment of precancerous
lesions and CC included the resources associated with
general practitioner (GP)/specialist visits, diagnostic pro-
cedures, treatments and hospitalisations. The reference
unit costs (year 2013) for each of these identified re-
sources were obtained from the South Africa Uniform Pa-
tient Fee Schedule (UPFS) [35] or from the literature
when not available in the database (see Additional file 2
for details). Weighted averages of resource use multi-
plied with unit costs were included as cost input data
into the model (Table 4). All costs are expressed in
South African Rand (ZAR). Cost data extracted from
the literature and reported in international dollar wereconverted to same year ZAR values using the Power-
Purchase-Parity (PPP) adjusted exchange rate between
ZAR and USD for the value year in the publication [36, 37].
These estimated same year ZAR values were then inflation-
adjusted to 2013 using the South African Consumer Price
Index data [38].
Vaccine costs
The 2013 list price of the AS04-adjuvanted HPV-16/18
vaccine of ZAR 595.39 per dose was used as the cost of
vaccine per dose [39]. The national tender price is likely
to be lower than its listed price; however, the tender
price is unknown. A 2-dose schedule was assumed
following the recent approval of the 2-dose schedule in
South Africa.
Vaccine effectiveness and coverage
A proxy vaccine effectiveness was used, based on the
most recent data on the AS04-adjuvanted HPV-16/18
vaccine efficacy reported for each endpoint irrespective
of the causative type in the lesion in the Total Vacci-
nated Cohort from the end-of-study results from the
PATRICIA trial [15]. Reported vaccine efficacy was used
as a proxy for effectiveness as follows: CIN1+ 50.3 %
(95 % CI: 40.2–58.8 %; CIN1 health state in the model),
CIN2+ 64.9 % (95 % CI: 52.7–74.2 %; CIN2/3 health
Table 2 HPV and HIV epidemiology and disease management input data
Parameter Annual probability
HIV- subpopulation Source HIV+ subpopulation Source
Mortality rate
General mortality rate Age 15: 0.09 % [65] Age 15: 0.10 % [65]
Age 30: 0.20 % Age 30: 4.62 %
Age 45: 0.51 % Age 45: 7.71 %
Age 60: 1.56 % Age 60: 29.72 %
Age 75: 5.31 % Age 75: 37.38 %
HPV and HIV incidence





Oncogenic HPV incidence 0.041–0.390 [59] 0.110–1.000 [59, 66]
Cervical cancer parameters
Cervical cancer mortality 0.110 [2] 0.291 [67]
Cervical cancer cured 0.151 [2] 0.027 [67]
HPV screening-related parameters
Screening coverage 13.6 % [59] 13.6 % [59]
Screening ages 30–60 years [63] 30–60 years [63]
Screening frequency Every 3 years WHO [27, 28] Every 3 years WHO [27, 28]
CIN1 detected 0.58 [68] 0.58 [68]
CIN2/3 detected 0.61 [68] 0.61 [68]
HPV-related disease management
Proportion of women treated if CIN1 is detected 0.50 Assumption 0.50 Assumption
CIN1 treatment success 0.90 Assumption 0.90 Assumption
Proportion of women treated if CIN2/3 is detected 1 Assumption 1 Assumption
CIN2/3 treatment success 0.90 Assumption 0.90 Assumption
ASSA, Actuarial Society of South Africa; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; HIV, human immunodeficiency virus;
HIV-, HIV-negative; HIV+, HIV-positive; HPV, human papillomavirus; ICO, Institut Català d'Oncologia; Pap, Papanicolaou smear test
Table 3 Utility input data [29–33]
Health state Disutility value Utility value (HIV-); baseline value = 1 Utility value (HIV+); baseline value = 0.81
No HPV 0 1 0.81
HPV-Onc 0 1 0.81
CIN1 0 1 0.81
CIN1 det 0.013 0.987 0.797
CIN2/3 0 1 0.81
CIN2/3 det 0.013 0.987 0.797
Cervical cancer 0.273 0.727 0.537
Cervical cancer cured 0.062 0.938 0.748
CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; det, detected; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+,
HIV + positive; HPV, human papillomavirus
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Table 4 Costs input data [36–38]
Intervention Costs (ZAR)
Cost of regular screening negative Pap smear 256
Regular screening + false positive 256 + 1 656 (assume 2 %
false positive)
Treatment CIN1 detected 830
Treatment CIN2/3 detected 2 464
Cervical cancer stage I-IV 40 507
CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2
or 3; Pap, Papanicolaou smear test
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health state) [15]. Vaccine efficacy in HIV+ subjects is
assumed to be the same as those reported for HIV- co-
hort in the PATRICIA trial, based on recently reported
immunogenicity results from a phase I/II clinical trial in
HIV+ women in South Africa showing the vaccine is im-
munogenic and does not impact on HIV disease pro-
gression in HIV+ women [16].
A vaccination schedule with 2 doses for the target
age-group was assumed, as recommended by the WHO
recently [40], and approved by the South African health
authorities. Vaccine efficacy for the 2-dose schedule
was assumed identical to the vaccine efficacy reported
for a 3-dose schedule based on the result of recent im-
munogenicity studies demonstrating non-inferiority of
a 2-dose vs. a 3-dose schedule [41–43]. In the base case
analysis, we assume 100 % vaccination coverage (which
does not impact the cost-effectiveness of the vaccine as
the model used has a static design) and lifetime
vaccine-induced protection in both HIV- and HIV+
subpopulations based on a mathematical modelling
prediction [44].
Discounting
In accordance with South Africa Pharmacoeconomic
Guidelines for economic evaluations, future costs and
outcomes were discounted at a rate of 5 % [35].
Data availability
All input data were retrieved from publicly available
sources and access to the ASSA2008 model was granted




For the base case analysis, a 2-dose AS04-adjuvanted
HPV-16/18 vaccine in combination with the current Pap
smear screening programme, compared with the current
Pap smear screening programme alone, was assessed.
Discounted and undiscounted cost, health outcomes,incremental values and cost-effectiveness ratios were
estimated.
According to the WHO recommendation for pharma-
coeconomic evaluations, an intervention can be consid-
ered cost-effective when the ICER is below the threshold
of 3 × gross domestic product (GDP) per capita [45] and
highly cost-effective below 1 x GDP per capita. GDP per
capita at current prices in South Africa was ZAR 66 764
in 2013 [36].
Scenario analyses
The cost-effectiveness of the AS04-adjuvanted HPV-16/
18 vaccine in a strictly hypothetical HIV+ population
was specifically modelled as for the base case analysis.
When assessing the HIV+ subpopulation, the HPV in-
fection rate in the HIV- population was set to be 0, to
restrict the estimation of HPV related burden in the
HIV+ population. The vaccination cost was attributed
to girls that would become HIV+ over their lifetime.
The subject would acquire HIV according to the South
African incident rate and would be included in the HIV+
subpopulation. This analysis corresponds to a sub-
evaluation of girls of whom the future HIV status would
be known at the time of vaccination. Discounted and
undiscounted outcomes were investigated.
Sensitivity analysis
➢ Overall
To account for the uncertainty in model parameters,
a one-way sensitivity analysis on the discounted ICER
was performed, varying key parameters in the model
by ±20 % (x0.8 – x1.2) from their baseline values where
95 % confidence interval (CI) was not available. For
vaccine efficacy, the 95 % CI values were taken as
minimum and maximum values (see Additional file 3).
➢ HIV+ subpopulation
Although the vaccine efficacy and duration of protection
remains unknown in HIV+ subpopulation, we have
evaluated the impact of changes by means of one-way
sensitivity analysis on the discounted ICER, by varying
the vaccine effectiveness and vaccine duration of
protection using the following values:
 vaccine effectiveness: relative reduction of 5 % (×0.95)
to 30 % (×0.70) with a 5 % increment of the base
case value
 vaccine duration of protection: waning of immunity
from 5 to 50 years after initial vaccination, followed
by a booster dose for 40 % of the cohort at the time
of waning.
➢ Vaccine price
A vaccine price sensitivity analysis on the discounted
ICER varying the vaccine price with a range of 50 to
150 % of the list price per dose was performed.
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Impact of changes in HIV mortality and HIV incidence
rate on the discounted ICER were evaluated using a
two-way sensitivity analysis. The mortality was reduced
by 10 % (×0.90) to 50 % (×0.50) and HIV incidence
was varied by ±75 % (×0.25 – ×1.75). The HIV mortal-
ity under which the vaccine becomes highly cost-
effective among the overall population was estimated
by determining the reduction in HIV mortality under
which the ICER reached 1 × GDP per capita (highly
cost-effective).Fig. 2 Modelled vs. observed: (a) HIV prevalence, (b) cervical cancer incide
cancer incidence [58], cervical cancer mortality [59]. CC, cervical cancer; HIVProbabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was performed
for both base case and scenario analyses using @Risk
(Palisade Corporation, Ithaca, New York, USA) to test
parameter uncertainty and to evaluate the overall ro-
bustness of the model. Distributions were assigned to
transition probabilities, costs and utility using normal
distribution (limited from 0 to 1 for probabilities) where
confidence intervals were available, otherwise, uniform
distribution was assigned ranging from 20 % above
and below the base case value (see Additional file 4).nce, (c) cervical cancer mortality. Sources: HIV prevalence [57]; cervical
, human immunodeficiency virus; HIV+, HIV-positive; HIV-, HIV-negative




The Markov cohort model adequately reproduced the
age-dependent HIV prevalence rate, CC incidence and
CC mortality rate for South Africa, as reported in Fig. 2.
The modelled CC incidence and mortality rate in the
HIV+ subpopulation was significantly higher compared
with the HIV- subpopulation. This could however not be
validated against observed data as these do not exist.
Base case analyses
Undiscounted and discounted costs and outcomes
comparing CC screening in addition to HPV vaccin-
ation with CC screening alone for a single cohort of
12-year-old girls in South Africa are reported in
Table 5. By implementing HPV vaccination, 8 869
(undiscounted) CC cases and 5 436 CC deaths (undis-
counted) could be prevented over the lifetime of a sin-
gle cohort of girls in South Africa. Total incremental
undiscounted cost was ZAR −663 748 191 and 68 270
QALY were gained. The undiscounted results thus
show that the HPV vaccination programme added to
the current CC screening programme is dominantTable 5 Base case results: overall 12-years-old girls cohort
Outcomes Screening Screening + H
NO DISCOUNTING
Total costs ZAR 1 649 427 899 ZAR 985 679 7
Vaccine cost ZAR 0 ZAR 628 612 7
Screening cost ZAR 149 297 117 ZAR 153 547 7
CIN1 treatment cost ZAR 10 577 161 ZAR 3 746 430
CIN2/3 treatment cost ZAR 8 262 222 ZAR 1 813 136
CC treatment cost ZAR 1 481 291 399 ZAR 197 959 5
Life years 27 173 430 27 230 436
CC cases 10 244 1 376
CC deaths 6 313 877
QALYs 26 554 764 26 623 034
DISCOUNTED AT 5 %
Total costs ZAR 221 807 577 ZAR 692 872 2
Vaccine cost ZAR 0 ZAR 628 612 7
Screening cost ZAR 35 277 421 ZAR 36 453 10
CIN1 treatment cost ZAR 2 775 840 ZAR 1 007 252
CIN2/3 treatment cost ZAR 2 541 718 ZAR 553 386
CC treatment cost ZAR 181 212 598 ZAR 26 245 77
Life years 1 283 817 9 154 639
QALYs 8 904 494 8 910 240
CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3,
HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; V + S, HPV vaover the CC screening programme alone. Discounted
results reported were ZAR 471 064 695 overall cost
difference and 5 746 QALY gained, resulting in an
ICER of 81 978 ZAR/QALY. Thus, HPV vaccination
with the AS04-adjuvanted HPV-16/18 vaccine can be
considered to be cost-effective according to the WHO
recommendations [36, 45].Scenario analysis
In the scenario analysis specific for the HIV+ subpopula-
tion, a total of 1 813 CC cases (undiscounted) and 1 707
CC deaths (both undiscounted) could be prevented over
the lifetime of the cohort. Total undiscounted cost dif-
ference with CC screening alone resulted in ZAR −46
418 189 and a QALY gain of 7 248 for a single cohort of
girls aged 12 in South Africa, thus resulting in the HPV
vaccination programme added to the current cervical
screening programme to be dominant over the CC screen-
ing programme alone in a HIV+ subpopulation. Dis-
counted at 5 %, results reported were ZAR 136 358 673
overall cost difference and 1 331 QALY gained, resulting
in an ICER of 102 479. Thus, HPV vaccination with the
AS04-adjuvanted HPV-16/18 vaccine can be considered
to be cost-effective according to the WHO recommenda-
tions in this specific subpopulation [36, 45] (Table 6).PV vaccination Incremental value ICER (ZAR/QALY)
08 ZAR −663 748 191
62 ZAR 628 612 762
88 ZAR 4 250 671
ZAR −6 830 731
ZAR −6 449 086




68 270 V + S dominant
71 ZAR 471 064 695
62 ZAR 628 612 762
1 ZAR 1 175 681
ZAR −1 768 588
ZAR −1 988 332
0 ZAR −1 988 332
4 633
5 746 ZAR 81 978
CIN grade 2 or 3; QALYs, quality-adjusted life-years; ZAR, South African Rand;
ccination + screening
Table 6 Scenario results: HIV+ subpopulation
Outcomes Screening Screening + HPV vaccination Incremental value ICER (ZAR/QALY)
NO DISCOUNTING
Total costs ZAR 295 251 951 ZAR 248 833 762 ZAR −46 418 189
Vaccine cost ZAR 0 ZAR 183 228 152 ZAR 183 228 152
Screening cost ZAR 19 794 328 ZAR 21 262 010 ZAR 1 467 682
CIN1 treatment cost ZAR 3 641 306 ZAR 557 658 ZAR −3 083 648
CIN2/3 treatment cost ZAR 3 545 580 ZAR 561 971 ZAR −2 983 609
CC treatment cost ZAR 268 270 736 ZAR 43 223 970 ZAR −225 046 766
Life years 3 179 736 3 186 707 6 971
CC cases 2 161 348 −1 813
CC cancer deaths 2 035 328 −1 707
QALYs 2 573 677 2 580 925 7 248 V + S dominant
DISCOUNTED AT 5 %
Total costs ZAR 62 169 185 ZAR 198 527 858 ZAR 136 358 673
Vaccine cost ZAR 0 ZAR 183 228 152 ZAR 183 228 152
Screening cost ZAR 5 766 054 ZAR 6 223 334 ZAR 457 279
CIN1 treatment cost ZAR 1 126 206 ZAR 177 452 ZAR −948 755
CIN2/3 treatment cost ZAR 1 183 601 ZAR 190 676 ZAR −992 925
CC treatment cost ZAR 54 093 324 ZAR 8 708 245 ZAR −45 385 079
Life years 1 283 817 1 285 076 1 259
QALYs 1 039 522 1 040 852 1 331 ZAR 102 479
CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; QALYs, quality-adjusted life-years, ZAR, South African Rand;
HPV, human papillomavirus, ICER, incremental cost-effectiveness ratio; V + S, HPV vaccination + screening
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One-way sensitivity analyses on variation of key vari-
ables and the resulting ICER are reported in Fig. 3,
showing that variation in the discount rate had the
greatest impact on ICER estimates. For the overall
population base case analysis (Fig. 3a), vaccine efficacy
in HIV- subpopulation, HPV progression rate and vac-
cine efficacy in HIV+ subpopulation had a significant
impact on the ICER. In the sensitivity analysis specific
to the HIV+ subpopulation (Fig. 3b), main drivers of
ICER estimates were HPV progression rate, vaccine ef-
ficacy and baseline utility in the HIV+ subpopulation.
In the overall population analysis, with 50 % increase
in the vaccination price (Fig. 4a), results show that HPV
vaccination is still cost-effective. When the vaccine price
is reduced by 25 %, HPV vaccination becomes highly
cost-effective in South Africa. In the HIV+ subpopula-
tion analysis, the price range between highly cost-
effective and cost-effective vaccination price is between
ZAR 450 and 950 per vaccine dose respectively (Fig. 4b).
When the impact of vaccine efficacy (Fig. 5) on ICER
estimates was assessed, results show that HPV vaccin-
ation remained cost-effective in the overall population
when vaccine efficacy was reduced by 30 %. However, in
the HIV+ subpopulation analysis, HPV vaccination be-
came not cost-effective if vaccine efficacy was reducedby 25 %. A similar trend was observed for the impact on
the duration of protection in the HIV+ subpopulation
(Fig. 6) with the discounted ICER remaining below the
cost-effectiveness threshold in the overall population but
rapidly rose above the threshold if the duration of pro-
tection was shorter than 15 years in the HIV+
subpopulation.
The two-way sensitivity analysis reported in Table 7
demonstrates that with changes in HIV incidence
(−75 to +75 %) and HIV mortality rate (from no
change to −50 %) vaccination remained cost-effective
or highly cost-effective in all scenarios in the overall
population.
In the HIV+ subpopulation, a 22 % decrease in the
HIV mortality rate, at current HIV incidence, lead to
HPV vaccination becoming highly cost-effective (< 1 ×
GDP per capita) (Fig. 7).
The results of the probabilistic sensitivity analysis are
reported in the acceptability curve in (Fig. 8), which
presents the cumulative probability in function of dis-
counted ICER analysis. The probability of ICER being
below the threshold (3 × GDP per capita) is 99 % for
base case and 98 % for scenario. It shows that the sce-
nario analysis has a slower slope towards the maximum
indicating that the spread of the samples has a larger
interval than for the base case. This may be due to
Fig. 3 One-way sensitivity analyses: (a) base case analysis, (b) scenario analysis. BC, base case; CI, confidence interval; CIN, cervical intraepithelial
neoplasia; CIN1/2/3, CIN grade 1, 2 or 3; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV-positive;
HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; Pap, Papanicolaou test; pop, population
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subjected to uncertainty than for the base case.
The results indicate that even under parameter vari-
ation, HPV vaccination in South Africa is likely to be
cost-effective in all target groups showing the import-
ant public health impact of vaccination in this setting.
Discussion
We evaluated the cost-effectiveness of a CC prevention
programme in South Africa where HPV vaccination is
added to the current CC screening programme. In this
evaluation, we explicitly accounted for the existing HIV+
population in South Africa that have specific HPV-related disease history and hence a potential impact on
the value of a HPV programme. To our knowledge, no
analysis of this kind has been previously reported. The
base case analysis (including 29 % HIV+ and 71 % HIV-
over the lifetime of a single cohort of 12-year-old South
African girls) showed that this strategy would be cost-
effective when compared with CC screening alone. Simi-
lar conclusions have been previously reported in other
settings although these analyses did not include HIV+
subpopulations [22, 23, 29, 46, 47].
Evidence exists demonstrating that the acquisition and
progression of HPV is faster in HIV+ individuals making
them more at risk of HPV-related cancers [7, 20, 48, 49].
Fig. 4 One-way price sensitivity analysis: (a) base case analysis, (b) scenario analysis. BC, base case; GDP, gross domestic product; HIV, human
immunodeficiency virus; HIV+, HIV-positive; ICER, incremental cost-effectiveness ratio; ZAR, South African Rand
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to the HIV- positive and negative populations to account
for the specificities of the acquisition and natural history
of HPV infection in these two subpopulations, as docu-
mented by a recent systematic literature review [25].
Moreover, there is no sufficient evidence in the literature
that HIV treatments have effect on the HPV natural
history [50]. Vaccination would likely be the only way to
effectively prevent the increased risk of HPV and HPV-
related outcomes in a HIV+ population.
In this modelling exercise, HPV vaccination was
considered for a cohort of HPV and HIV naïve South
African 12-year-old girls. These girls may become HPV
and/or HIV positive post vaccination. A specific scenario
analysis on HIV+ population was conducted. This repre-
sents the population target at the age of vaccination as
at that age we assumed no existing HIV infection. The
modelled outcomes suggest that HPV vaccination
remained cost-effective under the WHO recommended
cost-effectiveness threshold in the overall population aswell as in the HIV+ subpopulation, although the ICER
(ZAR 102 479 per QALY gained) is higher than the one
estimated for the overall population (ZAR 81 978 per
QALY gained). Decrease in overall HIV- associated mor-
tality rate for the HIV+ population would make HPV
vaccination more attractive as more disease can be
avoided in later life. Given current mortality rates in
HIV+ women, most HIV+ women may die before they
develop precancerous lesions, or indeed cancer, even
when HPV disease develops faster in HIV+ individuals.
With better access to HIV treatment in South Africa,
HIV incidence and mortality rate is however likely to
improve in the near future, and hence improve the cost-
effectiveness of the vaccination programme. Results were
most sensitive to variation of discount rate, vaccine
efficacy, duration of vaccine-induced protection in the
HIV+ subpopulation, HIV incidence and mortality rates
and HPV vaccine price. The parameter with the largest
impact on the ICER was the discount rate. A high dis-
count rate favours disease preventive interventions that
Fig. 5 Sensitivity analyses: impact of vaccine efficacy: (a) base case analysis, (b) scenario analysis. CC, cervical cancer; GDP, gross domestic
product; ICER, incremental cost-effectiveness ratio; ZAR, South African Rand
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ally, a high discount rate disfavours HPV vaccination as
CC take years or even decades to develop [51, 52]. A re-
cent update of the National Institute for Health and
Care Excellence (NICE) in the United Kingdom recom-
mends a discount rate of 1.5 % to be used in techno-
logical appraisals for diseases with an expected benefit
leading to prevention of death or a benefit that is sus-
tained for at least 30 years [53]. Applying this discount
rate would favour prevention of disease and death fur-
ther away in the future and improve cost-effectiveness
for HPV vaccination substantially (results not shown).A systematic literature review on the cost-effectiveness
of HPV vaccination in middle and low income countries,
including South Africa [54], found that most studies in
these countries concluded that HPV vaccination is likely
to be cost-effective or possibly even cost saving. An
evaluation in the South African context specifically con-
cluded that adding HPV vaccination can be considered
highly cost-effective [22]. Our study estimated a higher
ICER in the base case evaluation than the one reported
in this previous evaluation (ZAR 102 479 ~ USD 10 609
vs. USD 1 078 per QALY gained) from a public payers
perspective. Besides the inclusion of HIV-specific health
Fig. 6 Impact of duration of protection in HIV+ subpopulation: (a) overall population, (b) HIV+ subpopulation. BC, base case; CC, cervical cancer;
GDP, gross domestic product; HIV, human immunodeficiency virus; HIV+, HIV-positive; HIV-, HIV-negative; ICER, incremental cost-effectiveness ratio;
ZAR, South African Rand
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tween the two evaluations was driven by a lower 3 % dis-
count rate used in Sinanovic et al. evaluation compared
with the 5 % in the present evaluation. The Sinanovic
et al. study was indeed published before the issue of the
National Pharmacoeconomics Guideline mandating a
5 % discount rate as baseline [35]. Cytological screening
was used in both studies as screening strategy in South
Africa. Sinanovic et al. used 3 times screening at 10-
years interval starting at 30 years of age [22]. A screen-
ing with 3 years interval from age 30 to 60 years was
used in this analysis, as recommended by WHO and the
national guideline, if resources allow [27, 28]. A Pap
test was assumed, an HPV DNA testing, with higher
sensitivity and more automated process, may be recom-
mended as triage testing or replace the current screen-
ing in the future which would also impact the results.The treatment costs used in our study were based on a
Delphi panel resulting in lower costs than included in
the Sinanovic study which used updated costs from two
earlier publications [37, 55]. Finally, the vaccine cost
also differed. While the Sinanovic et al. study assumed
vaccination cost of USD 570 including 3 doses and a
booster rate of 50 %, administration, wastage and vac-
cination programmatic costs, we however applied the
vaccine price with the 2-dose schedule (ZAR 595.39
using listed price) based on the recent regulatory
update.
Another population-level modelling study assessed the
economic impact of the different CC prevention (screen-
ing and vaccination) in Sub-Saharan African countries. It
demonstrated that HPV vaccination alone is highly cost-
effective in South Africa when price per course is USD
100 (ICER = USD 4 900 per life year saved). The authors
Table 7 Two way sensitivity analysis: mortality and incidence rates in HIV+ subpopulation
Incidence HIV+ mortality
(base case)
HIV+ mortality−10 % HIV+ mortality−20 % HIV+ mortality−30 % HIV+ mortality−40 % HIV+ mortality−50 %
NO DISCOUNTING
−75 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
−50 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
−25 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
Base case V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
25 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
50 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
75 % V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant V + S dominant
DISCOUNTED AT 5 %
−75 % 85 537 84 256 82 724 80 862 78 551 75 609
−50 % 83 958 81 600 78 845 75 590 71 693 66 948
−25 % 82 798 79 513 75 754 71 421 66 383 60 466
Base case 81 978 77 880 73 275 68 080 62 189 55 473
25 % 81 435 76 610 71 279 65 375 58 824 51 540
50 % 81 116 75 635 69 667 63 167 56 089 48 385
75 % 80 979 74 896 68 362 61 352 53 842 45 817
The bold zone indicates the ICER is < 1 × GDP per capita (ZAR 66 764); V + S, HPV vaccination + screening
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ture modelling [56].
The tender price is likely to be lower than the listed
price, which would further improve the cost-effectiveness
of the vaccine compared with no vaccination. However
under variation of the vaccine price (from 50 % decreaseFig. 7 Sensitivity analyses: impact of HIV mortality rate in the HIV+ subpop
immunodeficiency virus; HIV+, HIV-positive; ICER, incremental cost-effectiveto 50 % increase), HPV vaccination remained cost-
effective. Therefore higher vaccination cost including e.g.
administration costs or wastage would still result in the
vaccine to be cost-effective in South Africa. In this ana-
lysis, all scenarios used the cost of a 2-dose vaccination
schedule, reducing the price of the vaccine, comparedulation. CC, cervical cancer; GDP, gross domestic product; HIV, human
ness ratio; QALY, quality-adjusted life years; ZAR, South African Rand
Fig. 8 Cost-effectiveness acceptability curves for the base case and scenario analysis. ZAR, South African Rand
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using a 2-dose schedule may alleviate not only issues
related to overall vaccination budget (also including e.g.
administration, vaccine storage, transportation, …) but
additionally increase acceptability and hence compliance
of the vaccine. These elements were not accounted for in
this presented analysis [41].
Limitations of this analysis exist. The Markov model
used here is a static model and therefore no dynamic
effects such as herd protection were taken into account.
Only the direct vaccine effect was considered which
provides a conservative estimation of the effect of vac-
cination. Furthermore, adaptation of a dynamic model
would require detailed inputs data for both HIV+ and
HIV- population which would be very challenging to
obtain and, hence, requiring many assumptions to be
made which could drive the results of the analysis and
add uncertainties. The use of a static model does also
add transparency to both the analysis and data selec-
tion. The difference in HIV prevalence rate from age 20
to 45 between the model and the observed data (see
Fig. 2) may be due to observed data being reported
based on an annual cross-sectional population survey
while the model follows a single age-cohort over life-
time based on today’s epidemiology and HIV treatment
practice.
Most of the country-specific data in South Africa are
reported at the population level (including both HIV+
and HIV- subpopulations). It is therefore very challen-
ging to extract different parameters for either subpopu-
lation from the reported data. Therefore, several
conservative assumptions had to be made with regards
to parameters for disease progression or CC mortality
rate. Also, comparison with HIV+ specific CC incidencewas not possible as such data are not reported anywhere.
Furthermore, children born with HIV were not included
in this analysis. Since the model follows HPV disease
progression in both HIV-infected and uninfected popu-
lation, this model implicitly assumes that HIV was ac-
quired by sexual transmission.
Our analysis also did not address inequities in health-
care access that may exist in and between populations in
South Africa. Access to CC screening may not be readily
available for all women in South Africa leading to excess
risk of this cancer in unscreened women [29]. HPV vac-
cination given to girls age 12 may, to a certain extent,
improve access to prevention of CC for large groups in
the population thereby creating more opportunities for
individual development and generation of well-being.
Moreover, there is not sufficient evidence that treat-
ment of HIV has effect on HPV natural history in the
literature; vaccination would likely be the only way to
effectively alleviate the increased risk of HPV and HPV-
related outcomes in HIV+ girls.
Although studies using mathematical simulation
modelling cannot replace clinical trial-based evaluation,
model-based analyses provide important information
that can help prioritise and guide the implementation
of healthcare choices in South Africa.
However, this analysis highlights that potential reduc-
tion in the future incidence of HIV in a population may
impact the cost-effectiveness value of an HPV vaccine
by lowering the ICER value. Also, this analysis high-
lights that reduction in HIV mortality, which can be ex-
pected with new treatments, would also improve the
cost-effectiveness of the vaccination. This should be
taken into account when implementing a vaccination
programme among girls that for some will develop HIV
Li et al. BMC Infectious Diseases  (2015) 15:566 Page 16 of 18and hence could benefit more or benefit less of the
programme depending on the future of HIV treatments
or epidemiology.Conclusions
Findings from this modelling exercise suggest that the
introduction of the 2-dose AS04-adjuvanted HPV-16/18
vaccine in South Africa added to the current CC screening
programme may lead to a strong reduction in the number
of CC cases and related deaths in the HIV+ as well as the
HIV- subpopulations and may be a cost-effective interven-
tion in both the general overall female population and the
HIV+ female subpopulation alike. Improvement in HIV
treatment leading to better survival among the HIV+ fur-
ther improved the cost-effectiveness of the implementa-
tion of a HPV vaccination programme in countries with
high HIV prevalence such as South Africa.Endnotes
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